Phase II study of a novel oral formation of 5-fluorouracil in combination with low-dose cisplatin as preoperative chemotherapy of oral squamous cell carcinoma

International Journal of Clinical Pharmacology Research

Volumn 25, Issue 3, 2005, Pages 115-122

  Nakazawa, M ^a   Ohnishi, T ^b   Ohmae, M ^c   Chisoku, H ^d   Yui, S ^e   Iwai, S ^a   Sumi, T ^a   Fukuda, Y ^f   Kishino, M ^a   Yura, Y ^a  

^a OSAKA UNIVERSITY   (Japan)

^b Ikeda Municipal Hospital   (Japan)

^c Izumisano Municipal Hospital   (Japan)

^d OSAKA CITY GENERAL HOSPITAL   (Japan)

^e TENRI HOSPITAL   (Japan)

^f OSAKA UNIVERSITY DENTAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; HEMOGLOBIN; TS 1;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM DISEASE; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; FEMALE; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENCE; LEUKOPENIA; LOW DRUG DOSE; MALE; MOUTH CARCINOMA; NAUSEA; NEUTROPENIA; NEUTROPHIL; PHASE 2 CLINICAL TRIAL; PIGMENT DISORDER; PREOPERATIVE PERIOD; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; TOXICITY; TUMOR BIOPSY; URTICARIA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM STAGING; OXONIC ACID; PREOPERATIVE CARE; PYRIDINES; TEGAFUR;

EID: 28344456765     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Collins S.L., Weichselbaum R.R., Dougherty M., Stupp R., Vokes E.E. Head and neck. In: Abelloff M.D., Armitage J.O., Licher A.S., Niederheber J.E. (Eds.) "Clinical Oncology." Churchill Livingstone, New York, 1995, pp. 961-1022.
2. Kish J.A., Drelichman A., Jacobs J., et al. Clinical trial of cisplatinum and 5-FU infusion as initial treatment for advanced squamous carcinoma of the head and neck. Cancer Treat. Rep., 66, 471, 1982.
3. Kish J.A., Weaver A., Jacobs J., et al. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer, 53, 1819, 1984.
4. Kohno N., Ikari T., Kawaida M., et al. Survival results of neoadjuvant chemotherapy for advanced squamous cell carcinoma of the head and neck. Jpn. J. Clin. Oncol., 30, 253, 2000.
5. El-Sayed S., Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: A meta-analysis of prospective and randomized trials. J. Clin. Oncol., 14, 838, 1996.
6. Munro A.J. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br. J. Cancer, 71, 83, 1995.
7. Pignon J.P., Bourhis J., Domenge C., et al. Chemotherapy added or locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet, 355, 949, 2000.
8. Taguchi T. UFT: Biochemical modulation for 5-fluorouracil (5-FU). Chin. Med. J. Engl., 110, 294, 1997.
9. Nakazawa M., Iwai S., Moriyama T., et al. The histological antitumor effect and side effects of preoperative chemotherapy for patients with oral squamous cell carcinoma - comparison between low-dose and high-dose CDDP regimens. Jpn. J. Cancer Chemother. (Gan To Kagaku Ryoho) (Jpn), 28, 337, 2001.
10. Shirasaka T., Shimamoto Y., Ohshimo H., et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-Cancer Drugs, 7, 548, 1996.
11. Ogawa M. Novel anticancer drugs in Japan. J. Cancer Res. Clin. Oncol., 125, 134, 1999.
12. Inuyama Y., Kida A., Tsukuda M., et al. Early phase II study of S-1 in patients with advanced head and neck cancer. Jpn. J. Cancer Chemother. (Gan To Kagaku Ryoho) (Jpn), 25, 1151, 1998.
13. Inuyama Y., Kida A., Tsukuda M., et al. Late phase II study of S-1 in patients with advanced head and neck cancer. Jpn. J. Cancer Chemother. (Gan To Kagaku Ryoho) (Jpn), 28, 1381, 2001.
14. World Health Organization. Handbook for reporting results of cancer treatment. WHO Offset Publication No. 48, Geneva, Switzerland, WHO, 1979.
15. Shimosato Y., Oboshi S., Baba K. Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas. Jpn. J. Clon. Oncol., 1, 19, 1971.
16. Hong W.K., Bromer R. Chemotherapy in head and neck cancer. N. Engl. J. Med., 308, 75, 1983.
17. Hong K.W. Adjuvant chemotherapy for respectable squamous cell carcinoma of the head and neck. Report on intergroup study 0034. Int. Radiat. Oncol. Biol. Phys., 23, 885, 1992.
18. Adelstein D.J., Sharan V.M., Earle A.S., et al. Simultaneous versus sequential combined technique therapy for squamous cell head and neck cancer. Cancer, 65, 1685, 1990.
19. Ancona E., Ruol A., Santi S. Only pathologic complete response to neoadjuvant chemotherapy improved significantly the long term survival of patients with resectable esophageal squamous cell carcinoma. Final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer, 91, 2165, 2001.